Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Receivables: 2024

Historic Receivables for Syndax Pharmaceuticals (SNDX) over the last 1 years, with Dec 2024 value amounting to $11.2 million.

  • Syndax Pharmaceuticals' Receivables was N/A to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.7 million, marking a year-over-year change of. This contributed to the annual value of $11.2 million for FY2024, which is N/A change from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Receivables stood at $11.2 million for FY2024.
  • Syndax Pharmaceuticals' Receivables' 5-year high stood at $11.2 million during FY2024, with a 5-year trough of $11.2 million in FY2024.
  • In the last 1 years, Syndax Pharmaceuticals' Receivables had a median value of $11.2 million in 2024 and averaged $11.2 million.